[go: up one dir, main page]

BR9915940A - Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53 - Google Patents

Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53

Info

Publication number
BR9915940A
BR9915940A BR9915940-6A BR9915940A BR9915940A BR 9915940 A BR9915940 A BR 9915940A BR 9915940 A BR9915940 A BR 9915940A BR 9915940 A BR9915940 A BR 9915940A
Authority
BR
Brazil
Prior art keywords
protein
methods
family
restore
compositions
Prior art date
Application number
BR9915940-6A
Other languages
English (en)
Inventor
Heather Anne Coffey
Richard Damian Connell
Barbara Ann Foster
Farzan Rastinejad
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9915940A publication Critical patent/BR9915940A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>"MéTODOS E COMPOSIçõES PARA RESTAURAR A ESTABILIDADE CONFORMACIONAL DE UMA PROTEìNA DA FAMìLIA p53"<D>. A invenção situa-se no campo do tratamento do câncer. Em particular, a presente invenção proporciona compostos farmacêuticos capazes de interação com formas mutantes e não-mutantes de proteínas reguladoras relacionadas com câncer tal que a proteína mutante recupera a capacidade de interagir apropriadamente com outras macromoléculas, restaurando ou estabilizando por esse meio toda ou uma porção da sua atividade do tipo selvagem. As proteínas reguladoras incluem membros da família de proteínas p53 tais como, por exemplo, p53, p63 e p73. Os compostos da invenção são úteis para o tratamento do câncer. Métodos para triar tais compostos farmacológicos são também fornecidos.
BR9915940-6A 1998-12-02 1999-12-01 Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53 BR9915940A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11054298P 1998-12-02 1998-12-02
PCT/IB1999/001916 WO2000032175A2 (en) 1998-12-02 1999-12-01 METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY

Publications (1)

Publication Number Publication Date
BR9915940A true BR9915940A (pt) 2001-09-11

Family

ID=22333594

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915940-6A BR9915940A (pt) 1998-12-02 1999-12-01 Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53

Country Status (25)

Country Link
US (1) US20020048271A1 (pt)
EP (1) EP1137418A2 (pt)
JP (2) JP2002531396A (pt)
KR (1) KR20010086073A (pt)
CN (1) CN1329493A (pt)
AP (1) AP2001002153A0 (pt)
AU (1) AU1290700A (pt)
BG (1) BG105599A (pt)
BR (1) BR9915940A (pt)
CA (1) CA2350597A1 (pt)
EA (1) EA003326B1 (pt)
EE (1) EE200100302A (pt)
HK (1) HK1041644A1 (pt)
HR (1) HRP20010414A2 (pt)
HU (1) HUP0201215A2 (pt)
ID (1) ID29061A (pt)
IL (1) IL143094A0 (pt)
IS (1) IS5943A (pt)
NO (1) NO20012737L (pt)
OA (1) OA11722A (pt)
PL (1) PL348310A1 (pt)
TR (1) TR200101549T2 (pt)
WO (1) WO2000032175A2 (pt)
YU (1) YU35401A (pt)
ZA (1) ZA200104210B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US20030022243A1 (en) * 2001-06-20 2003-01-30 Les Kondejewski Protein aggregation assays and uses thereof
JP2005510460A (ja) * 2001-08-10 2005-04-21 メディカル リサーチ カウンシル 分子
US20050221324A1 (en) * 2002-05-06 2005-10-06 Fox Michael H Genotoxicity analysis
AU2003258662A1 (en) * 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4-amino-quinazolines as anti cancer agents
PT1470818E (pt) * 2003-04-25 2006-11-30 Neuro3D Utilização de derivados de fenotiazina piperazina no fabrico de um medicamento com efeitos neuroprotectores e/ou neurotróficos no cns e/ou pns
US6970791B1 (en) * 2003-05-23 2005-11-29 Verachem, Llc Tailored user interfaces for molecular modeling
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
KR101218213B1 (ko) * 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
US20070099950A1 (en) * 2003-11-21 2007-05-03 Jongwon Lim Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain
EP1709973A1 (en) * 2003-12-24 2006-10-11 Locomogene, Inc. Method of suppressing cancer
WO2005061007A1 (ja) * 2003-12-24 2005-07-07 St. Marianna University School Of Medicine 癌の抑制方法
AU2005251735A1 (en) * 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc COMPOUNDS AND ITS THERAPEUTIC USE
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
CA2615373A1 (en) * 2005-07-15 2007-01-25 Schering Corporation Quinazoline derivatives useful in cancer treatment
US7790474B1 (en) 2005-07-15 2010-09-07 Schering Corporation p53 modulators
US8232298B2 (en) 2006-03-22 2012-07-31 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and P53
DE602007007065D1 (de) 2006-03-22 2010-07-22 Janssen Pharmaceutica Nv Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
NZ546477A (en) * 2006-04-07 2009-04-30 Auckland Uniservices Ltd 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy
CA2657246C (en) * 2006-07-10 2017-10-31 Donald Landry Anti-cocaine compositions and treatment
WO2008155441A1 (en) * 2007-06-20 2008-12-24 Marikki Laiho Activators and therapeutic applications thereof
ES2510551T3 (es) * 2007-07-10 2014-10-21 The Trustees Of Columbia University In The City Of New York Termoestabilización de proteínas
PA8792401A1 (es) 2007-08-06 2009-03-31 Janssen Pharmaceutica Nv Fenilendiaminas
MY152018A (en) 2009-02-04 2014-08-15 Janssen Pharmaceutica Nv Indole derivatives as anticancer agents
US20130102627A1 (en) * 2010-04-09 2013-04-25 The Brigham And Women's Hospital, Inc. Acridines As Inhibitors Of Haspin And DYRK Kinases
WO2012154879A2 (en) 2011-05-09 2012-11-15 Van Andel Research Institute Autophagy inhibitors
US9187439B2 (en) 2011-09-21 2015-11-17 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
CN102660257B (zh) * 2012-05-22 2013-11-27 南京邮电大学 吩噻嗪基喹唑啉类荧光离子探针及其应用
RS58244B1 (sr) * 2014-09-30 2019-03-29 Diadem S R L Antitelo koje vezuje linearni epitop humanog p53 i njegove dijagnostičke primene
CN105399670B (zh) * 2015-12-02 2018-04-17 广西中医药大学 一种苯并(c)吖啶酰胺基硫脲衍生物及其制备方法和用途
CN105399671B (zh) * 2015-12-02 2018-04-17 广西中医药大学 7‑对甲苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途
CN105418501B (zh) * 2015-12-02 2018-04-17 广西中医药大学 7‑对甲氧苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途
RU2762089C2 (ru) 2016-02-04 2021-12-15 Иеда Рисеч Энд Девелопмент Ко. Лтд. ПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, НАРУШЕНИЙ ИЛИ СОСТОЯНИЙ, АССОЦИИРОВАННЫХ С МУТАНТНЫМ р53
AU2017221472B2 (en) * 2016-02-19 2023-01-05 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
CN109694358B (zh) * 2019-01-23 2022-02-08 广西师范大学 2-对硝苯乙烯基-4-取代氨基喹唑啉衍生物及其制备方法和应用
PH12022550707A1 (en) * 2019-09-23 2023-03-27 Pmv Pharmaceuticals Inc METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
US20210405056A1 (en) * 2020-06-24 2021-12-30 Pmv Pharmaceuticals, Inc. Methods for detecting mutant p53 function
WO2021262484A1 (en) 2020-06-24 2021-12-30 Pmv Pharmaceuticals, Inc. Combination therapy for treatment of cancer
GB202111035D0 (en) * 2021-07-30 2021-09-15 Vestlandets Innovasjonsselskap As Therapy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224784D0 (en) * 1992-11-26 1993-01-13 Univ Dundee Cellular protein
DK0746613T3 (da) * 1994-03-08 2006-09-25 Sloan Kettering Inst Cancer Rekombinante humaniserede antistoffer mod FB5
NZ279963A (en) * 1994-12-13 1998-10-28 Human Genome Sciences Inc Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
US6107332A (en) * 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
US6270954B1 (en) * 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
EP0959877A4 (en) * 1996-04-10 2000-08-23 Univ California CORRECTION OF GENETIC ERRORS USING CHEMICAL COMPANIES
DE19624154A1 (de) * 1996-06-18 1998-01-08 Hoechst Ag Ringannelierte Dihydropyrane, Verfahren zur Herstellung sowie deren Verwendung
US5932613A (en) * 1996-07-03 1999-08-03 Millennium Pharmaceuticals, Inc. Anticancer agents
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
TR199900382T2 (xx) * 1996-08-28 1999-05-21 The Procter & Gamble Company Heterosiklik metaloproteaz inhibit�rleri.
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6387673B1 (en) * 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
US6284923B1 (en) * 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
US6387903B1 (en) * 1997-08-27 2002-05-14 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6399638B1 (en) * 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
FI105554B (fi) * 1998-05-13 2000-09-15 Galilaeus Oy Geenimuunnelluista Streptomyces galilaeus-kannoista saatavat hybridiantrasykliinit
US6395749B1 (en) * 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
ATE279411T1 (de) * 1998-08-12 2004-10-15 Daiichi Pure Chemicals Co Ltd Fluorszierende marker
SE9900941D0 (sv) * 1998-12-23 1999-03-16 Nomet Management Serv Bv Novel retinoic acid derivatives and their use
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
WO2000066125A1 (en) * 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6406699B1 (en) * 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
WO2001028550A1 (en) * 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia
US6372785B1 (en) * 2000-05-04 2002-04-16 Keith Chan, President Globoasia, Llc Synthesis of 1,8-dichloro-anthracene analogues and pharmaceutical compositions based thereon
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
US6395771B1 (en) * 2000-05-31 2002-05-28 Dabur Research Foundation Paclitaxel derivatives for the treatment of cancer
US6391916B1 (en) * 2000-07-21 2002-05-21 The Hong Kong University Of Science And Technology Enediyne derivatives

Also Published As

Publication number Publication date
PL348310A1 (en) 2002-05-20
HUP0201215A2 (en) 2002-08-28
EP1137418A2 (en) 2001-10-04
BG105599A (en) 2002-02-28
EA003326B1 (ru) 2003-04-24
EA200100502A1 (ru) 2001-12-24
YU35401A (sh) 2005-07-19
CN1329493A (zh) 2002-01-02
IL143094A0 (en) 2002-04-21
IS5943A (is) 2001-05-15
AP2001002153A0 (en) 2001-06-30
CA2350597A1 (en) 2000-06-08
NO20012737D0 (no) 2001-06-01
JP2006166920A (ja) 2006-06-29
AU1290700A (en) 2000-06-19
JP2002531396A (ja) 2002-09-24
TR200101549T2 (tr) 2001-11-21
NO20012737L (no) 2001-07-09
HK1041644A1 (zh) 2002-07-19
ID29061A (id) 2001-07-26
WO2000032175A2 (en) 2000-06-08
EE200100302A (et) 2002-08-15
ZA200104210B (en) 2003-02-24
KR20010086073A (ko) 2001-09-07
OA11722A (en) 2005-01-25
US20020048271A1 (en) 2002-04-25
HRP20010414A2 (en) 2002-06-30
WO2000032175A3 (en) 2000-08-03

Similar Documents

Publication Publication Date Title
BR9915940A (pt) Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53
DK0600866T3 (da) Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
TR200002616T2 (tr) Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
BR9711098B1 (pt) compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
DK0428038T3 (da) Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
DE69020862D1 (de) Anlage zur Verabreichung steriler Flüssigkeiten, insbesondere pharmazeutischer, nahrhafter oder energetischer Flüssigkeiten.
BR9811249A (pt) Nova formulação para inalação; apresentando densidade volumétrica, quando derramada, de 0,20 à 0,38g/ml, processo para preparação de formulação e uso da mesma
EA199901031A1 (ru) Производные бензимидазола
SE9802729D0 (sv) Novel Compounds
DE60021898D1 (de) Reverse-turnmimetika und damit zusammenhängendes verfahren
FI956168A0 (fi) Uudet kemialliset yhdisteet, joilla on PDE-IV:ää inhiboivaa aktiivisuutta
BR0016227A (pt) Derivados de adamantano
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
DK0904110T3 (da) Nitrogenoxid-afgivende sammensætninger til nedsættelse af lægemidlers toksicitet
CO4290432A1 (es) Nuevos derivados de pirazinacarboxamida, su preparacion y su utilizacion en medicamentos.
DE69919379D1 (de) Komplexe von hyaluronic saure/carnitinen und pharmazeutische und kosmetische zusammensetzungen
ES2109260T3 (es) Eritrocitos transformados, procedimiento para prepararlos y su utilizacion en composiciones farmaceuticas.
BR9913072A (pt) Sistemas de anel azacìclico, composição farmacêutica, e, processo para induzir a analgesia
ATE385517T1 (de) Interferon ähnliche moleküle, und deren verwendungen
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
BR0309412A (pt) Indol-2-onas como inibidores seletivos da ciclooxigenase-2
ATE8880T1 (de) Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.